Clinical studies have suggested that TMB may be useful in predicting the outcome of immunotherapy when looking at non–small cell lung cancer45; however, not all tumor types benefit from immunotherapy with high TMB.15 Additionally, EBV+ cells of lymphoproliferative disorders have been shown to express PD-L1 in immunocompetent patients, which may indicate immunotherapy susceptibility.46,47. The gene discussed is CD274; the disease is neoplasm.